Yitzhak Peterburg - Rosetta Genomics Director

Director

Dr. Yitzhak Peterburg serves as a director of the company, since December 2012. Dr. Peterburg has also served as a consultant to Rosetta since October 2012. He currently serves on the Board of Directors of TEVA Pharmaceuticals, prior to which he served as TEVAs Senior Vice President, Head of Global Branded Products, prior to which he served on the board of TEVA. Prior to his positions with TEVA, Dr. Peterburg was President and CEO of Cellcom, one of Israel leading cellular companies. Between the years of 1990 to 2002, Dr. Peterburg was with Clalit Health Services, a nongovernmental, notforprofit organization that provides comprehensive health services to more than 55 percent of the Israeli population. From 1997 to 2002 he served as General Manager for Clalit Health Services and from 1990 to 1997 he held a series of senior executive positions including Head, Health Policy Division and Chief Information Officer, Medical Division. Among his many positions at Clalit, from 19951997, Dr. Peterburg served as CEO of Soroka University Medical Center, BeerSheba, Israel, one of the biggest university hospitals in Israel since 2012.
Age 65
Tenure 12 years
Phone972 73 222 0700
Webhttp://www.rosettagx.com
Peterburg received an M.D. from the Hebrew University of Jerusalem, and holds a Ph.D. in health services administration from the Columbia University School of Public Health in New York and a master degree in information systems from the London School of Economics. Prof. Peterburg is a professor at the School of Business, BenGurion University.

Rosetta Genomics Management Efficiency

The company has return on total asset (ROA) of (60.19) % which means that it has lost $60.19 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (137.95) %, meaning that it created substantial loss on money invested by shareholders. Rosetta Genomics' management efficiency ratios could be used to measure how well Rosetta Genomics manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 2.45 M in liabilities with Debt to Equity (D/E) ratio of 222.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Rosetta Genomics has a current ratio of 2.05, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Rosetta Genomics until it has trouble settling it off, either with new capital or with free cash flow. So, Rosetta Genomics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Rosetta Genomics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Rosetta to invest in growth at high rates of return. When we think about Rosetta Genomics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Susan EllerbuschSummit Materials
53
Richard BeyerAnalog Devices
66
William StraussServiceNow
56
Kenton SicchitanoAnalog Devices
73
Ian McWalterEvertz Technologies Limited
58
Neil NovichAnalog Devices
63
Karen GolzAnalog Devices
63
Anne CooneySummit Materials
61
Adrian PertierraAsure Software
45
Thomas PistorEvertz Technologies Limited
N/A
Yves IstelAnalog Devices
79
Ronald CoddServiceNow
61
Charles LathropAsure Software
61
Paul ChamberlainServiceNow
56
Edward FrankAnalog Devices
61
John HodgsonAnalog Devices
71
Christopher ColcloughEvertz Technologies Limited
N/A
Charles GiancarloServiceNow
58
Anita SandsServiceNow
43
Julia KahrSummit Materials
37
Dennis WoodsideServiceNow
51
Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel. Rosetta Genomics operates under Diagnostics Research classification in USA and traded on Nasdaq Capital Markets. It employs 86 people. Rosetta Genomics (ROSG) is traded on NASDAQ Exchange in USA and employs 86 people.

Management Performance

Rosetta Genomics Leadership Team

Elected by the shareholders, the Rosetta Genomics' board of directors comprises two types of representatives: Rosetta Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rosetta. The board's role is to monitor Rosetta Genomics' management team and ensure that shareholders' interests are well served. Rosetta Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rosetta Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
David Sidransky, Independent Director
Kenneth Berlin, CEO and Pres
Anne Fields, IR Contact Officer
Joshua Rosensweig, Director
Dganit Bar, Chief Scientific Officer
Brian Markison, Chairman, Observer To Board of Directors and Member of Nominating and Corporate Governance Committee
Douglas Sites, Executive Vice President - Sales and Marketing
Tal YaronEldar, Independent Director
Eti Meiri, Vice President - Research
Robert Wassman, Chief Medical Officer
Oded Biran, General Counsel
Roy Davis, Director
Yitzhak Peterburg, Director
Kevin Watson, Director, Reimbursement-Managed Care
Ron Kalfus, CFO
Gerald Dogon, External Independent Director
Tali YaronEldar, External Independent Director

Rosetta Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rosetta Genomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Other Consideration for investing in Rosetta Stock

If you are still planning to invest in Rosetta Genomics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rosetta Genomics' history and understand the potential risks before investing.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon